BrainsWay Ltd. reiterated revenue guidance for the year 2024. The company is reiterating previously provided full-year 2024 revenue guidance of $37 million to $40 million. This would represent growth of 16% to 26% over full-year 2023 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,202 ILa | -5.13% | +10.28% | +4.61% |
Jun. 03 | Brainsway's Deep Transcranial Magnetic Stimulation Gets Expanded FDA Labeling; Shares Rise | MT |
Jun. 03 | BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.61% | 112M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.75% | 66.45B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B | |
+22.61% | 30.98B |
- Stock Market
- Equities
- BWAY Stock
- News BrainsWay Ltd.
- BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024